{"id":5479,"date":"2026-01-17T01:06:28","date_gmt":"2026-01-16T22:06:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5479"},"modified":"2026-01-17T01:06:30","modified_gmt":"2026-01-16T22:06:30","slug":"atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Atossa Therapeutics, Duchenne Musk\u00fcler Distrofisinin Tedavisi \u0130\u00e7in (Z)-Endoxifen'e FDA Yetim \u0130la\u00e7 Onay\u0131 Ald\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Atossa Therapeutics, ABD G\u0131da ve \u0130la\u00e7 \u0130daresi'nin (\"FDA\") Nadir Hastal\u0131k \u00dcr\u00fcnleri Geli\u015ftirme Ofisi'nin, Duchenne kas distrofisi (\"DMD\") tedavisi i\u00e7in (Z)-endoxifen'e Nadir Hastal\u0131k \u0130lac\u0131 Stat\u00fcs\u00fc verdi\u011fini duyurdu. &gt;&gt; <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/dmdwarrior.com\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" rel=\"noreferrer noopener\">Atossa Therapeutics, (Z)-Endoxifen i\u00e7in FDA Nadir Pediatrik Hastal\u0131k Tan\u0131m\u0131 Ald\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cAtossa Therapeutics Ba\u015fkan\u0131 ve CEO'su Steven C. Quay, MD, Ph.D., yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, \"Daha \u00f6nce ald\u0131\u011f\u0131m\u0131z Nadir Pediatrik Hastal\u0131k stat\u00fcs\u00fcne ek olarak, Duchenne kas distrofisinde (Z)-endoxifen i\u00e7in Yetim \u0130la\u00e7 stat\u00fcs\u00fc, bu ciddi ve zay\u0131flat\u0131c\u0131 hastal\u0131k i\u00e7in (Z)-endoxifen'i geli\u015ftirme yolunda ilerlerken Atossa i\u00e7in \u00f6nemli bir kilometre ta\u015f\u0131d\u0131r\" dedi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Atossa, geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131nda ilerledik\u00e7e FDA ile ileti\u015fimini s\u00fcrd\u00fcrmeyi planl\u0131yor ve gerekti\u011finde g\u00fcncellemeler sa\u011flayacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Atossa Therapeutics, announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (&#8220;DMD&#8221;). >> Learn More: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen &#8220;In addition to the previously received Rare Pediatric Disease designation, Orphan [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5480,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[461,462,464,463],"class_list":["post-5479","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-z-endoxifen","tag-atossa-therapeutics","tag-endoxifen","tag-tamoxifen"],"subtitle":"Atossa Therapeutics, FDA'nin Duchenne kas distrofisi tedavisi i\u00e7in (Z)-endoxifen'e Yetim \u0130la\u00e7 Stat\u00fcs\u00fc verdi\u011fini duyurdu.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5479"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5479\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5480"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}